Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Sana Biotechnology Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 20× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 3,963,319). Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Sana Biotechnology Inc for 23 Days on average.
| IEI | SANA | |
|---|---|---|
Market Cap | $16.72B | $836.71M |
Volume | 3,963,319 | 4,507,444 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $5.92 |
52-Week Low | $113.17 | $2.68 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.49 with minimal daily movement, up 0.1%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent corporate actions include consistent dividend payments. The bond market environment, highlighted by rising Treasury yields, influences sentiment, with news pointing to volatility in interest rates affecting fixed-income related assets.
The outlook remains cautious due to bearish technical signals and macroeconomic pressures from rising yields. Investment opportunities include dividend consistency, but risks involve interest rate sensitivity and market volatility. A neutral to bearish stance is warranted pending clearer fundamental data or stabilization in bond markets.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
